Literature DB >> 6671136

Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody.

A C Tate, E R DeSombre, G L Greene, E V Jensen, V C Jordan.   

Abstract

The aim of this study was to compare and contrast the interaction of estrogen [( 3H]17 beta-estradiol)- or antiestrogen [( 3H]monohydroxytamoxifen)-receptor complexes from human breast tumor cytosols with monoclonal antibodies raised to the human breast tumor estrogen receptor. Breast tumor cytosols containing estrogen receptor which sedimented as radiolabeled peaks in either the 8S, 8S and 4S, or 4S regions of sucrose density gradients, interacted with the monoclonal antibody D547 to produce a broad 9-10S peak, a broad 8S-10S peak, or a more discrete 8S peak, respectively. On high salt (0.4M KC1) sucrose density gradients the 4S ligand-receptor complex plus antibody produced a binding peak at approximately the 8S region of the gradient. These sedimentation studies with the monoclonal antibody D547, and similar studies with the monoclonal antibody D58, could detect no differences in the cytosolic estrogen receptor whether complexed with [3H]estradiol or with [3H]monohydroxytamoxifen. These observations were confirmed by Scatchard equilibrium saturation analysis and sucrose density gradient analysis of cytosols from the MCF-7 human breast cancer cell line. The antibody D547 interacted with 8S ER from these cytosols to produce a broad 8S-10S peak, but the antibody produced no change in the affinity or number of binding sites present in these cytosols. It seems, therefore, that the antigenic determinants recognized by these particular antibodies on the breast tumor cytosolic receptor are not significantly altered by the binding of either an estrogen or an antiestrogen to the receptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6671136     DOI: 10.1007/bf01806700

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Antiestrogens in the treatment of breast cancer.

Authors:  S S Legha; S K Carter
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

2.  Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model.

Authors:  V C Jordan; K E Allen
Journal:  Eur J Cancer       Date:  1980-02       Impact factor: 9.162

3.  Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat.

Authors:  K Sudo; F J Monsma; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1983-02       Impact factor: 4.736

4.  Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo.

Authors:  V C Jordan; R A Bowser-Finn
Journal:  Endocrinology       Date:  1982-04       Impact factor: 4.736

5.  Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. Differences with anti-estrogen and estrogen.

Authors:  R L Eckert; B S Katzenellenbogen
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

6.  Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors.

Authors:  G L Greene; F W Fitch; E V Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

7.  Interaction of a high affinity anti-estrogen (alpha-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-alpha'-nitrostilbene, CI628M) with uterine estrogen receptors.

Authors:  B S Katzenellenbogen; E J Pavlik; D W Robertson; J A Katzenellenbogen
Journal:  J Biol Chem       Date:  1981-03-25       Impact factor: 5.157

8.  Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis.

Authors:  V C Jordan; G Prestwich
Journal:  Mol Cell Endocrinol       Date:  1977-09       Impact factor: 4.102

9.  The transformation of the cytoplasmic oestradiol-receptor complex into the nuclear complex in a uterine cell-free system.

Authors:  M Gschwedt; T H Hamilton
Journal:  Biochem J       Date:  1972-07       Impact factor: 3.857

10.  High-affinity binding of the antiestrogen [3H]tamoxifen to the 8S estradiol receptor.

Authors:  F Capony; H Rochefort
Journal:  Mol Cell Endocrinol       Date:  1978 Jul-Aug       Impact factor: 4.102

View more
  4 in total

1.  The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.

Authors:  V Craig Jordan
Journal:  Ann Surg Oncol       Date:  2019-03-25       Impact factor: 5.344

Review 2.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor.

Authors:  P M Martin; Y Berthois; E V Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

Review 4.  Structure-activity relationships of estrogens.

Authors:  V C Jordan; S Mittal; B Gosden; R Koch; M E Lieberman
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.